Novartis Investigative Site

Kuei-Shan Chiang, Taoyuan/ Taiwan ROC 33305

0 studies enrolling now · 8 studies all time

What they study most

Acute Myeloid Leukemia (AML), Advanced Gastric Cancer, Advanced NET of GI Origin, Advanced NET of Lung Origin, Advanced Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Gastro-esophageal Junction Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Neuroendocrine Tumors, Recurrent Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) — Completed
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) — Completed
• A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Stopped early
• Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer — Completed
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations — Stopped early
• A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation — Completed
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer — Completed
• Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) — Completed